FOGHORN THERAPEUTICS INC (FHTX)

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients...

FHTX Makes Notable Cross Below Critical Moving Average

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing...

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into...

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H....

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with...

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior...

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1...

Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and...

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

/PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the...

A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore

/PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, and Flagship Pioneering, the bioplatform...

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Foghorn Therapeutics to Participate in the BMO Oncology Summit

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...

Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Mirai Bio, a company pioneering the first open end-to-end platform for...

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/PRNewswire/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to...

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/CNW/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on...

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...

Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer

/PRNewswire/ -- Flagship Pioneering today demonstrated further acceleration in its strategic partnership with Pfizer Inc, announcing two research programs with...

Bullish Two Hundred Day Moving Average Cross - FHTX

FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Foghorn Therapeutics (NASDAQ:FHTX) just reported results for the second quarter...

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth...

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and...

GSK and Flagship Pioneering partner to discover novel medicines and vaccines

/PRNewswire/ -- GSK plc (LSE/NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a...

Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World

/PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, and Flagship Pioneering, the bioplatform innovation company, today announced...

Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new...